APA

Mustonen T., Rauma I., Hartikainen P., Krüger J., Niiranen M., Selander T., Simula S., Remes A. M. & Kuusisto H. (20210118). Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation. : Multiple sclerosis and related disorders.

Chicago

Mustonen Tiina, Rauma Ilkka, Hartikainen Päivi, Krüger Johanna, Niiranen Marja, Selander Tuomas, Simula Sakari, Remes Anne M and Kuusisto Hanna. 20210118. Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation. : Multiple sclerosis and related disorders.

Harvard

Mustonen T., Rauma I., Hartikainen P., Krüger J., Niiranen M., Selander T., Simula S., Remes A. M. and Kuusisto H. (20210118). Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation. : Multiple sclerosis and related disorders.

MLA

Mustonen Tiina, Rauma Ilkka, Hartikainen Päivi, Krüger Johanna, Niiranen Marja, Selander Tuomas, Simula Sakari, Remes Anne M and Kuusisto Hanna. Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation. : Multiple sclerosis and related disorders. 20210118.